Small Molecule Drug Development Services
Accelerating leukemia drug development requires partners with deep disease biology expertise. Alfa Cytology delivers targeted small molecule discovery through integrated computational and experimental platforms, with validated hits advancing to IND-enabling studies.
Overview of Small Molecule Drug
About 80% of approved therapies are small-molecule drugs, which are organic compounds characterized by their low molecular weight. Researchers investigate new angles to uncover newer drugs for leukemia that would target novel mechanisms of disease initiation and help design new interventions arresting or reversing the spread of the disease. The process of drug discovery consists of the identification of pharmacologically active candidates, their characterization, synthesis, screening, and evaluation of therapeutic efficiency.
Fig. 1. Stages of drug discovery and development process. (Deore, A.B. et al., 2019)
Small molecule drugs are those that have low molecular weight. Their small size and good chemical properties make them applicable for easy penetration into the gastrointestinal tract and rapid absorption into the bloodstream. They also cross cellular membranes very easily, giving rise to therapeutic actions. Alfa Cytology renders comprehensive services relating to small molecule drug development, some of which include:
Leverage functional genomics (CRISPR dropout screens) and proteomic profiling to uncover leukemia dependencies like MCL-1 or BCL-2 isoforms. Targets are validated in primary patient-derived co-cultures.
High-Throughput Drug Screening
This offer is for high-throughput screening services providing fast testing of large numbers of individual compounds in the quest for compounds that modulate the activity of biological targets. Our resources include over a million compounds in our screening library that can be deployed for hit identification.
By offering complete support in the transition between hit compounds and lead candidates, our Hit-to-Lead Services strive to position and accelerate promising candidates towards becoming actual leads.
Using expertise in medicinal chemistry, computer-aided drug design, pharmacokinetics, ADME/DMPK, the company helps clients in designing their compounds optimally, hoping to discover the most active candidate compound.
Drug Resistance Services
Drug resistance remains a major hindrance to effective therapy and a significant challenge for leukemia. Address drug resistance mechanisms through:
- NGS profiling of resistant clones
- Synergistic combination screening
- CRISPR-engineered resistance models
Contact Us
Alfa Cytology is rich in drug development data for leukemia, allowing them a better idea of how different stages of molecular development are requiring customized solutions. Tailored solutions to allow clients to maximize the chances of repurposed target discovery while anticipating challenges at every stage of development. Contact us to discover how we can serve you.
Reference
- Deore, A.B.; et al. The stages of drug discovery and development process. Asian Journal of Pharmaceutical Research and Development. 2019, 7(6): 62-67.